Key clinical point: Meta-analysis showed a significant association between the use of fostamatinib and a higher risk for hypertension in patients with rheumatoid arthritis (RA); however, no association was observed with elevated risk for cardiovascular events.
Major findings: Fostamatinib was associated with significantly higher risk for hypertension compared with placebo (relative risk, 3.82; 95% confidence interval [CI], 2.88-5.05); however, it was not associated with the higher risk for all-cause death (Peto odds ratio [pOR], 0.16; 95% CI, 0.02-1.24), major adverse cardiovascular events (pOR, 1.24; 95% CI, 0.26-5.97), and other forms of heart disease (pOR, 1.96; 95% CI, 0.72-5.38).
Study details: This was a meta-analysis of 12 trials including 5,618 patients with RA who were treated with oral fostamatinib.
Disclosures: This study was supported by the Post-doctoral Research and Development Fund of West China Hospital, the Clinical Research Incubation Project of West China Hospital, and the Sichuan Science and Technology Program. The authors declared no conflict of interests.
Source: Chen Y et al. Front Pharmacol. 2021 Jul 19. doi: 10.3389/fphar.2021.632551 .